Fadogia agrestis as 'natty TRT': what the evidence actually says
Quick answer
The creator positions fadogia agrestis as a practical alternative to prescribed testosterone replacement therapy for men with low testosterone, citing anecdotal increases of 300-700 ng/dL. No human clinical trial data supports testosterone-boosting efficacy at any dose in humans, and animal studies have raised safety flags around testicular toxicity at higher exposures. Men presenting with symptomatic low testosterone should pursue serum testosterone and LH testing through a licensed clinician before considering any supplement intervention.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @shad_asiama actually say?
The creator claims that fadogia agrestis, a "Nigerian shrub," can raise testosterone by "three to 400 points" in most people, with one dramatic case going from the low 200s to the 700 range. He also says it makes "the testes grow" noticeably, boosts energy, accelerates recovery, and positions it as a legitimate alternative for people who can't get prescribed TRT. He ends with a product link and a "thank me later" guarantee.
To be clear: he's describing a supplement as capable of delivering outcomes that rival or approach clinical testosterone therapy. That's a significant claim, and it deserves scrutiny proportional to how confidently he made it.
Does the science back this up?
No, not remotely at the scale he's describing. The human evidence for fadogia agrestis is essentially nonexistent. Every meaningful study comes from rodents, and extrapolating rat data to human testosterone physiology is one of the oldest mistakes in supplement marketing.
The most-cited animal study (Yakubu et al., 2005, Asian Journal of Andrology) found that fadogia agrestis extract increased testosterone in male rats, along with testicular changes. Sounds promising until you realize rats are not small humans, and luteinizing hormone signaling, Leydig cell density, and hepatic metabolism differ enough that rodent testosterone responses routinely fail to replicate in humans. A follow-up by the same group (Yakubu et al., 2008, Journal of Ethnopharmacology) actually flagged potential testicular toxicity at higher doses in rats, which is the opposite of the "testes grow" selling point the creator uses. There are no published randomized controlled trials in humans demonstrating fadogia agrestis raises testosterone by any measurable amount, let alone 300 to 700 points. The "outlier" case he describes, someone going from the low 200s to 700 ng/dL, has no citation, no context, and no verification. A change that large in a clinically hypogonadal man would typically require actual TRT.
What did they get wrong (or right)?
Wrong on the numbers. A 300-700 ng/dL increase from an oral supplement with zero human trial data is not a reasonable claim. It's a sales pitch dressed as anecdote. The creator offers no bloodwork, no timeframe, no controlling for confounders like sleep, diet, or training changes. "Most people are gonna see about a three to 400 point increase" is stated as if it's an established clinical finding. It isn't.
Wrong on mechanism framing. Saying it makes "the testes grow" as a positive feature glosses over the fact that testicular enlargement from a pharmacologically active compound is not inherently safe or desirable, especially given the Yakubu 2008 toxicity signals.
Partially right on one thing: low testosterone does make muscle building harder. That part is well-supported (Bhasin et al., 2001, New England Journal of Medicine). But acknowledging a real problem doesn't validate an unproven solution.
- Claim that 600 mg is a standard effective dose: no human dose-response data exists to support this.
- Claim about "synergistic" effects with another compound: the transcript cuts off before naming it, making this unverifiable.
- Recovery benefits: no human evidence cited or available.
What should you actually know?
If your testosterone is genuinely low, a supplement with only rat-study backing is not the clinical answer. Hypogonadism is a diagnosable condition with established treatments, and self-treating based on a TikTok product link carries real risks, including delay of actual diagnosis and exposure to compounds with unknown human safety profiles.
The FDA does not regulate supplements for efficacy. A product can be sold legally while having no credible evidence it does what the label claims. Fadogia agrestis products on the market vary widely in purity and actual alkaloid content, which makes the creator's confident dosing statements even less meaningful.
If you're concerned about testosterone, get a blood panel. A clinician can tell you whether your levels are actually low, whether the drop is symptomatic, and what evidence-based options exist. That conversation is more useful than any supplement stack, and it doesn't require thanking anyone later.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Fadogia agrestis as 'natty TRT': what the evidence actually says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Fadogia agrestis as 'natty TRT': what the evidence actually says is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Claim verdict
The useful answer behind this video
Claim being checked
The creator positions fadogia agrestis as a practical alternative to prescribed testosterone replacement therapy for men with low testosterone, citing anecdotal increases of 300-700 ng/dL.
FormBlends verdict
The creator positions fadogia agrestis as a practical alternative to prescribed testosterone replacement therapy for men with low testosterone, citing anecdotal increases of 300-700 ng/dL. No human clinical trial data supports testosterone-boosting efficacy at any dose in humans, and animal studies have raised safety flags around testicular toxicity at higher exposures. Men presenting with symptomatic low testosterone should pursue serum testosterone and LH testing through a licensed clinician before considering any supplement intervention.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator positions fadogia agrestis as a practical alternative to prescribed testosterone replacement therapy for men with low testosterone, citing anecdotal increases of 300-700 ng/dL. No human clinical trial data supports testosterone-boosting efficacy at any dose in humans, and animal studies have raised safety flags around testicular toxicity at higher exposures. Men presenting with symptomatic low testosterone should pursue serum testosterone and LH testing through a licensed clinician before considering any supplement intervention.
- Zero published human RCTs have tested whether fadogia agrestis raises testosterone in men at any dose.
- The primary cited study (Yakubu et al., 2005) used rats, not humans, and rat testosterone physiology does not reliably predict human outcomes.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Zero published human RCTs have tested whether fadogia agrestis raises testosterone in men at any dose.
- The primary cited study (Yakubu et al., 2005) used rats, not humans, and rat testosterone physiology does not reliably predict human outcomes.
- A follow-up animal study (Yakubu et al., 2008, Journal of Ethnopharmacology) identified potential testicular toxicity signals at higher doses, contradicting the safety framing in the video.
- A 300-700 ng/dL testosterone increase from an oral supplement would be clinically extraordinary and has no supporting human evidence.
- Low testosterone is a diagnosable condition. Serum testosterone and LH testing through a licensed provider is the appropriate first step, not a supplement purchase.
- The FDA does not evaluate supplements for efficacy before they reach market, meaning product claims are not independently verified.
- Supplement purity and alkaloid content in fadogia agrestis products vary significantly, making any confident dosing claim from an influencer essentially meaningless without third-party testing data.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Shad Asiama · TikTok creator
6.3K views on this video
This doctor exposed the “natty trt” supplement #fadogiaagrestis #fitness
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Shad Asiama, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.